LEGAL PROCEEDINGS (Details) (USD $) In Millions, unless otherwise specified	1 Months Ended		12 Months Ended			1 Months Ended
	Feb. 28, 2010 Glumetza Apotex Inc. mg	Feb. 28, 2010 Aplenzin Watson mg	Dec. 31, 2011 Aplenzin Watson patent action	Dec. 31, 2011 Aplenzin Paddock patent	Dec. 31, 2011 Aplenzin Par patent	Jun. 30, 2010 Wellbutrin XL Valeant Pharmaceuticals International, Inc. Shareholders' equity mg	Mar. 31, 2010 Bupropion Hydrobromide Tablets Paddock mg	Sep. 30, 2010 Bupropion Hydrobromide Tablets Par mg	Jan. 31, 2012 Fluorouracil topical cream, 0.5% Spear Pharmaceuticals, Inc	May 31, 2008 Written plea agreement Biovail Pharmaceuticals, Inc.	May 31, 2008 Non-prosecution agreement Biovail Pharmaceuticals, Inc.	Sep. 30, 2009 Corporate Integrity Agreement Biovail Pharmaceuticals, Inc.	Oct. 31, 2009 General civil actions case
Legal proceedings and other matters
Penalty fees										$ 22.2	$ 2.4
Obligation term (in years)												5 years
Dosage strength (in mg)	500	174				150	174	174
Alternate dosage strength (in mg)		348				300	522	348
Period of stay on approval (in months)		30 months							30 months
Number of actions consolidated into the first-filed case			2
Number of the patents that remain in the litigation			5
Number of patents listed in the FDA's Orange Book				6	8
Number of cases settled													3